Nanoviricides, Inc. · AMEX:NNVC

Nanoviricides — IPO Roadshow (December 2019)

25 slides from Nanoviricides's IPO roadshow presentation, Dec 17, 2019

Slide 1: Corporate Presentation December 2019
Slide © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE - Amer.: NNVC) Slide ‹$OO5LJKWV5HVHUYHG1DQR9LULFLGHV,QF$3XEOLFO\7UDGHG&RPSDQ\ 1<6( $PHU119& 3UHVHQWHGE\ $QLO5'LZDQ3K' 3UHVLGHQW ([HF&KDLUPDQ 0RELOH DGLZDQ#QDQRYLULFL
Slide 2: Disclaimer and free writing prospectus notice
Slide ‹$OO5LJKWV5HVHUYHG1DQR9LULFLGHV,QF$3XEOLFO\7UDGHG&RPSDQ\ 1<6( $PHU119& 6OLGH © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE - Amer.: NNVC) NanoViricides , Inc. (the “Company”) has filed a Registration Statement on Form S - 1 (including a prelim
Slide 3: Presentation Layout
6OLGH © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE - Amer.: NNVC) 6OLGH ‹$OO5LJKWV5HVHUYHG1DQR9LULFLGHV,QF$3XEOLFO\7UDGHG&RPSDQ\ 1<6( $PHU119& Presentation Layout Industry - Leading Platform Technology Exclusively Licensed from TheraCour Pharma, In
Slide 4: Novel Platform Technology: A nanoviricide is a Cell Mimic
Slide ‹$OO5LJKWV5HVHUYHG1DQR9LULFLGHV,QF$3XEOLFO\7UDGHG&RPSDQ\ 1<6( PNW119& 6OLGH ‹$OO5LJKWV5HVHUYHG1DQR9LULFLGHV,QF$3XEOLFO\7UDGHG&RPSDQ\ 1<6( PNW119& 1RYHO3ODWIRUP7HFKQRORJ\$QDQRYLULFLGHŠLVD&HOO0LPLF 4 A nanoviricide “Looks Like” a Human Cell to th
Slide 5: A NanoViricide Attacking a Virus Particle
6OLGH ‹$OO5LJKWV5HVHUYHG1DQR9LULFLGHV,QF$3XEOLFO\7UDGHG&RPSDQ\ 1<6( PNW119& Slide © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE - mkt: NNVC) 5 A NanoViricide® Attacking a Virus Particle: Unique, Novel, Nanotech Design %,1' (1&$368/$7( '(6752<
Slide 6: Nanoviricides Dismantling MCMV Virus Particle
Slide © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE - mkt: NNVC) Slide ‹$OO5LJKWV5HVHUYHG1DQR9LULFLGHV,QF$3XEOLFO\7UDGHG&RPSDQ\ 1<6( PNW119& 1DQRYLULFLGHV'LVPDQWOLQJ0&099LUXV3DUWLFOH &RQWURO Treated $ C Virus Dismantled; Capsids Spilling Out A: i
Slide 7: NanoViricides is a Unique Drug Developer with Own cGMP Capability
Slide © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE - Amer.: NNVC) 6OLGH © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE - Amer.: NNVC) NanoViricides is a Unique Drug Developer Company with Its Own cGMP - Capable Manufacturing Capability Nano
Slide 8: Platform Technology Has Enabled Several Drug Programs
Slide © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE - Amer.: NNVC) 6OLGH © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE - Amer.: NNVC) 8 FluCide™ Injectable FluCide™ Oral HIVCide™ DengueCide™ Other Programs: Platform Technology Potentially O
Slide 9: HerpeCide Program Pipeline
Slide © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE - Amer.: NNVC) 6OLGH © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE - Amer.: NNVC) 9 VZV Lead Drug Candidate NV - HHV - 101 HSV - 2 HSV - 1 Herpes Keratitis Acute Retinal Necrosis Shingles
Slide 10: NanoViricides' Regulatory Strategy
Slide ‹$OO5LJKWV5HVHUYHG1DQR9LULFLGHV,QF$3XEOLFO\7UDGHG&RPSDQ\ 1<6( $PHU119& Slide © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE - Amer.: NNVC) NanoViricides’ Regulatory Strategy 'HUPDO7RSLFDO'UXJDV)LUVW&DQGLGDWH !4XLFNHU3DWK UDWKHUWKDQV
Slide 11: Lead Drug Candidate NV-HHV-101: Business Case
Slide ‹$OO5LJKWV5HVHUYHG1DQR9LULFLGHV,QF$3XEOLFO\7UDGHG&RPSDQ\ 1<6( $PHU119& Slide Lead Drug Candidate NV - HHV - 101: Business Case Potentially Billion+ Dollar Market for Topical Shingles Rash Treatment alone, even after the new vaccine Shingrix® has been introduced 500,000 to
Slide 12: Lead Drug Candidate NV-HHV-101 Status
6OLGH © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE - Amer.: NNVC) Slide Lead Drug Candidate NV - HHV - 101 Status - Getting Ready for IND Filing Indication: Shingles Rash Treatment. Form: Topical Skin Cream Anticipate Human Clinical Trials to Begin in CY 2020 Q1/Q2 FDA
Slide 13: Investment Thesis: Platform Technology and Facility
Slide ‹$OO5LJKWV5HVHUYHG1DQR9LULFLGHV,QF$3XEOLFO\7UDGHG&RPSDQ\ 1<6( $PHU119& 6OLGH © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE - Amer.: NNVC) Investment Thesis: NanoViricides Platform Technology and Facility Platform Technology - A “Venus - Fly -
Slide 14: Investment Thesis: NanoViricides Valuation
6OLGH © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE - Amer.: NNVC) Slide ‹$OO5LJKWV5HVHUYHG1DQR9LULFLGHV,QF$3XEOLFO\7UDGHG&RPSDQ\ 1<6( $PHU119& Investment Thesis: NanoViricides Valuation Company Founded and taken public (reverse shell merger) in 200
Slide 15: Shingles Rash: Unmet Medical Need
Slide ‹$OO5LJKWV5HVHUYHG1DQR9LULFLGHV,QF$3XEOLFO\7UDGHG&RPSDQ\ 1<6( $PHU119& Slide Shingles Rash breakouts - HHV - 3 aka VZV 8QPHW0HGLFDO1HHG$YDLODEOHGUXJVLQXVHQRWYHU\ HIIHFWLYH YDFFLQHVH[LVW 7KHFKLFNHQSR[YLUXVVXUYLYLQJLQJDQJOLDFDXVHV6KLQJOHVLQDGXOWV $ERX
Slide 16: Lead Drug Candidate NV-HHV-101
6OLGH © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE - Amer.: NNVC) Slide Lead Drug Candidate NV - HHV - 101 Dermal Topical Skin Cream for Treating Shingles Rash 6WDQGDUGRI&DUH9DOWUH[Š2UDOLV1RW9HU\(IIHFWLYH %HFDXVHYLUDO7.HQ]\PHDFWLYLW\UHTXLUHGIRUFRQYHUWL
Slide 17: Optimization Studies: VZV Topical Candidates Highly Effective
Slide ‹$OO5LJKWV5HVHUYHG1DQR9LULFLGHV,QF$3XEOLFO\7UDGHG&RPSDQ\ 1<6( $PHU119& Slide © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE - Amer.: NNVC) Optimization Studies VZV (Shingles) Topical Candidates Highly Effective - Five Times More Effective again
Slide 18: VZV Topical Drug Candidates Match Efficacy of Cidofovir
6OLGH © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE - Amer.: NNVC) VZV Infected Skin - Basal Layer Breaches seen, Also, Multinucleated Giant Cells seen Slide © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE - Amer.: NNVC) VZV (Shingles) Topica
Slide 19: VZV Topical Candidate Moving Rapidly To Clinical Trials
Slide © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE - Amer.: NNVC) Slide VZV (Shingles) Topical Candidate Moving Rapidly To Clinical Trials Preliminary Non - GLP Safety/Tolerability Studies in Rats Successful (2018) 19 1RFOLQLFDOO\REVHUYDEOHDGYHUVHVDIHW\DQGWR[LFRO
Slide 20: IND-Enabling Safety/Toxicology Package Studies
Slide © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE - Amer.: NNVC) 6OLGH 20 Non - GLP Portion of IND - Enabling Safety/Toxicology Studies Completed by BASi, IN ca. February, 2019 Excellent Safety Profile Observed cGMP Manufacture for GLP Safety/Toxicology Studies Comple
Slide 21: HerpeCide Program Future Expansion
Slide © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE - Amer.: NNVC) 6OLGH HerpeCide™ Program Future Expansion Epstein - Barr Virus: Mononucleosis Monoclonal Gammopathy other B - cell diseases, etc. Cytomegalovirus: Retinitis, Organ Transplant etc. HHV - 6A, HHV - 6B, HHV
Slide 22: Strong Executive Team
Slide © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE - Amer.: NNVC) Slide ‹$OO5LJKWV5HVHUYHG1DQR9LULFLGHV,QF$3XEOLFO\7UDGHG&RPSDQ\ 1<6( $PHU119& Strong Executive Team Anil R. Diwan, PhD President & Exec. Chairman Co - Founder Led Uplisting to NYSE -
Slide 23: Board of Directors
Slide ‹$OO5LJKWV5HVHUYHG1DQR9LULFLGHV,QF$3XEOLFO\7UDGHG&RPSDQ\ 1<6( $PHU119& Slide © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE - Amer.: NNVC) Board of Directors $QLO5'LZDQ3K' 3UHVLGHQW ([HF&KDLUPDQ &R )RXQGHU/HG8SOLVWLQJWR1<6( $P
Slide 24: Recap
Slide © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE - Amer.: NNVC) 5HFDS “Resistance is Futile” - Antiviral Nanomachines Designed to Destroy Viruses Despite Viral Mutations Broad and Deep Pipeline based on Platform Technology In - house cGMP Manufacture Enabling Early C

NanoViricides — IPO Roadshow (December 2019) on 6ix

Nanoviricides — IPO Roadshow (December 2019)

Slide 1: Corporate Presentation December 2019

Slide 2: Disclaimer and free writing prospectus notice

Slide 3: Presentation Layout

Slide 4: Novel Platform Technology: A nanoviricide is a Cell Mimic

Slide 5: A NanoViricide Attacking a Virus Particle

Slide 6: Nanoviricides Dismantling MCMV Virus Particle

Slide 7: NanoViricides is a Unique Drug Developer with Own cGMP Capability

Slide 8: Platform Technology Has Enabled Several Drug Programs

Slide 9: HerpeCide Program Pipeline

Slide 10: NanoViricides' Regulatory Strategy

Slide 11: Lead Drug Candidate NV-HHV-101: Business Case

Slide 12: Lead Drug Candidate NV-HHV-101 Status

Slide 13: Investment Thesis: Platform Technology and Facility

Slide 14: Investment Thesis: NanoViricides Valuation

Slide 15: Shingles Rash: Unmet Medical Need

Slide 16: Lead Drug Candidate NV-HHV-101

Slide 17: Optimization Studies: VZV Topical Candidates Highly Effective

Slide 18: VZV Topical Drug Candidates Match Efficacy of Cidofovir

Slide 19: VZV Topical Candidate Moving Rapidly To Clinical Trials

Slide 20: IND-Enabling Safety/Toxicology Package Studies

Slide 21: HerpeCide Program Future Expansion

Slide 22: Strong Executive Team

Slide 23: Board of Directors

Slide 24: Recap

Slide 25: The End